More than 400 cartons of Nilotinib capsules were voluntarily recalled by Cipla USA after failing manufacturing specifications ...
Cipla USA has recalled over 400 cartons of Nilotinib Capsules used to treat blood cancers after they failed to meet specifications, according to the U.S. Food and Drug Administration, which classified ...
Cipla USA Inc. the wholly owned subsidiary of Cipla Limited(BSE: 500087; NSE: CIPLA; and hereafter referred to as "Cipla") today announced the launch of Liraglutide Injection, 18 mg/3 mL (6 mg/mL) ...
Cipla USA, a subsidiary of the Indian drugmaker, is recalling over 400 cartons of generic anti-cancer drug Nilotinib due to a manufacturing issue. The recall is classified as Class III by the USFDA, ...
Cipla USA is voluntarily recalling over 400 cartons of its anti-cancer drug, Nilotinib Capsules, due to a manufacturing issue.
Cipla USA is recalling over 400 cartons of its anti-cancer drug Nilotinib Capsules. The recall is due to a manufacturing ...
Cipla USA recalls Nilotinib Capsules in the US due to manufacturing issues. USFDA Enforcement Report details the Class III voluntary recall.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results